Hello you wonderful and intelligent individuals that make up this forum. I sincerely hope you are doing well and are having another good week.
I have recently been looking into X4 Pharmaceuticals, the share price is at a historic low and there hopefully should be good news soon. The FDA are conducting a priority review into mavorixafor to treat patients 12 and older with WHIM (warts, hypogammaglobulinemia, infections and myelokathexis). There are no licensed therapies for WHIM, and the PDUFA date is 30th April 2024. Does anyone kindly think this is an interesting stock that may show strength up to the PDUFA date please as i know that FDA Priority Review drugs are also more likely to be approved? If anyone kindly had any thoughts on this i would be forever grateful and thankful it would mean the world to me.
Sending you lots of good wishes and i truly hope you achieve massive success with your investing. Have a fantastic week. Very best wishes.